Back to mobile site

Semler Scientific (SMLR) Announces CardioVanta

June 24, 2025 8:01 AM EDT

Semler Scientific, Inc. (Nasdaq: SMLR), the second U.S. public company to adopt Bitcoin as its primary treasury reserve asset and a leader in medical device and software to combat chronic diseases, announced that it has formed CardioVanta, Inc., a wholly-owned subsidiary that will comprise its future healthcare business activities focused on early detection of heart failure and cardiac arrythmia monitoring. CardioVanta will be structured as a high-margin, software-as-a-service (SAAS) business model. It will seek capital from outside investors to validate its long-term value and fund its relatively modest initial capital needs. The markets for early detection of heart failure and cardiac arrythmia monitoring are estimated in the multibillion-dollar range and are projected to grow substantially due to rising cardiovascular disease, technology advancements such as artificial intelligence, the aging population, and increasing adoption of wearable and remote monitoring solutions. According to the Centers for Disease Control and Prevention, heart failure affects more than six million Americans and costs the U.S. healthcare system more than $30 billion annually. While CardioVanta will focus on cardiac technology and care systems, Semler Scientific will continue marketing its QuantoFlo® device and software for early detection of peripheral artery disease.

"This exciting strategic plan aims to enhance our ability to combat chronic diseases, save more lives, and increase our Bitcoin holdings," said Eric Semler, chairman of Semler Scientific. "It represents a major opportunity for us to drive stockholder value and establish Semler Scientific as a dual-pronged powerhouse in the Bitcoin and medical technology sectors."

"This announcement today advances our long-term mission to empower individuals with both monetary freedom and cutting-edge healthcare solutions that improve access to early, preventative care," added Doug Murphy-Chutorian, chief executive officer of Semler Scientific. "We view Bitcoin not merely as a treasury asset, but as a representation of the same core principles that drive our medical mission: sustainability, transparency, and autonomy."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News

Related Entities

Definitive Agreement, Bitcoin, Maynard Um, Mark Zuckerberg, FDA, ARK